Seyed Mohammad Seifati

Seyed Mohammad Seifati

Auto-generated profile, based on publicly available information

Seyed Mohammad Seifati

Reproductive Immunology Research Center Shahid Sadoughi University of Medical Sciences Yazd Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HAHossein Ansariniya
Hossein Ansariniya
SSSeyed Mohammad Seifati
Seyed Mohammad Seifati
EZErfan Zaker
Erfan Zaker
FZFateme Zare
Fateme Zare
Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID‐19) infections are the three epidemiological diseases caused by the Coronaviridae family. Perceiving the immune responses in these infections and the escape of viruses could help us design drugs and vaccines for confronting these infections. This review investigates the innate and adaptive immune responses reported in the infections of the three coronaviruses SARS, MERS, and COVID‐19. Moreover, the present study can trigger researchers to design and develop new vaccines and drugs based on immune system responses. In conclusion, due to the need for an effective and efficient immune stimulation against coronavirus, a combination of several strategies seems necessary for developing the vaccine.

20 July 2021 in Biochemistry Research International
Verified
Journal Article
Open access
PDF file
SSSeyed Mohammad Seifati
Seyed Mohammad Seifati
EZErfan Zaker
Erfan Zaker
FFFarzaneh Fesahat
Farzaneh Fesahat
FZFateme Zare
Fateme Zare
SHSeyedhossein Hekmatimoghaddam
Seyedhossein Hekmatimoghaddam
The aims of this study are to investigate the effect of acrylamide on the level of proinflammatory cytokines in the blood of acrylamide-treated rats and to find the modulatory impact of probiotics on those cytokines. Thirty-two rats were divided into four groups: rats which received 20mg acrylamide, acrylamide with 20mg probiotics, acrylamide with 200mg probiotics, and standard water and food (groups 14, respectively). The serum levels of cytokines were measured on days 0, 15, and 30. Group 1 showed an increased serum level of IL-1β, IL-6, and TNF-α after 15 days, and they decreased in day 30. Serum IL-6 level was significantly decreased on days 15 and 30 in rats in group 2 compared to the controls. TNF-α and IL-1β levels were not statistically different after treated with probiotics. The exposure of rats to acrylamide led to increased systemic inflammation as evidenced by higher levels of proinflammatory cytokines, and probiotics can modulate this inflammation.

22 March 2022 in International Journal of Inflammation
Verified
Journal Article
Open access
PDF file
FFFarzaneh Fesahat
Farzaneh Fesahat
ENEfat Norouzi
Efat Norouzi
SSSeyed Mohammad Seifati
Seyed Mohammad Seifati
SHSaeideh Hamidian
Saeideh Hamidian
AHAkram A. Hosseini
Akram A. Hosseini
FZFateme Zare
Fateme Zare
Immune system disorders and increased inflammation in the male reproductive system can lead to fetal risk in the early stages of development and implantation. Antioxidants such as vitamin C can play a protective role against sperm inflammatory reactions. This study aimed to evaluate the effect of vitamin C on the expression of inflammatory and anti-inflammatory cytokine genes in the male partners of couples with recurrent pregnancy loss. In this randomized clinical trial, twenty male partners of couples with RPL were examined for sperm parameters and expression profile of some inflammatory and anti-inflammatory cytokine genes before and after treatment with vitamin C. There was a statistically significant higher rate of normal morphology and sperm concentration in each patient before and after treatment with vitamin C p ≤ 0.05 . The mRNA levels of interleukin 6 and tumor necrosis factor-alpha were significantly decreased in the sperm of patients after treatment with vitamin C compared to before treatment. In contrast, the gene expression levels of interleukin 4 and transforming growth factor-beta showed a significant increase in the sperm of patients after treatment with vitamin C. Oral daily administration of vitamin C may be effective in the fertility potential of male partners of couples with RPL not only through the improvement of the sperm parameters but also by modulating the expression profile of inflammatory and anti-inflammatory genes. Further studies on protein levels are needed to clarify the role of TNF-⍺ and IFN-γ as a prognostic value in evaluating the recurrent abortion risk in infertile male partners. This trial is registered with IRCT20180312039059N1.

1 January 2026 in Reproductive Medicine and Biology
Verified
Journal Article
Open access
SSSeyed Mohammad Seifati
Seyed Mohammad Seifati
FZFateme Zare
Fateme Zare
HAHossein Ansariniya
Hossein Ansariniya
FFFarzaneh Fesahat
Farzaneh Fesahat
SHSamaneh Harimi
Samaneh Harimi
HHHossein Hadinedoushan
Hossein Hadinedoushan
Purpose: Leukemia Inhibitory Factor (LIF) plays a crucial role in implantation and early pregnancy maintenance. However, its regulatory relationships with molecular markers such as Sirtuin 1 (SIRT1), immunoglobulin‐like transcript 4 (ILT‐4), and specific microRNAs (miRNA) in recurrent pregnancy loss (RPL) remain underexplored. Methods: This study investigates the effect of LIF on the expression of Sirt1 , Ilt‐4 , and related miRNAs using a mouse model of RPL. Female CBA/J mice mated with DBA/2 J males received LIF treatment. Gene and miRNA expression levels were assessed via quantitative PCR. Results: The LIF‐treated group showed significant upregulation of Sirt1 on Days 7 and 14. Ilt‐4 expression also increased significantly on Days 7 and 14 in the LIF group. Among miRNAs, mir‐138‐5p was significantly upregulated on Day 14 ( p = 0.0001), while mir‐223‐3p was downregulated on Days 7 ( p = 0.02) and 14 ( p = 0.001). mir‐199a‐5p showed significant downregulation on Days 7 ( p < 0.0001) and 14 ( p = 0.0001). Additionally, mir‐155‐5p demonstrated a significant decrease in the LIF‐treated group compared to the PBS group ( p < 0.0001). Conclusions: These results suggest that LIF modulates critical molecular pathways in RPL by influencing the expression of essential genes and miRNAs, highlighting its potential as a therapeutic target for pregnancy‐related complications.

8 July 2026 in Cancer Reports
Verified
Journal Article
Open access
SSSeyed Mohammad Seifati
Seyed Mohammad Seifati
HHHossein Hadinedoushan
Hossein Hadinedoushan
HAHossein Ansariniya
Hossein Ansariniya
FZFateme Zare
Fateme Zare
Leukemia inhibitory factor (LIF), a member of the IL‐6 cytokine family, is increasingly recognized as a tumor‐promoting factor in breast cancer, where it contributes to immune suppression, tumor progression, and therapy resistance. While neutralizing LIF is an attractive therapeutic approach, little is known about the systemic immunological consequences of targeting this cytokine. This study aimed to evaluate the effects of active immunization against recombinant LIF protein—designed to elicit endogenous anti‐LIF antibodies—on tumor progression and systemic cytokine responses in a murine breast cancer model. Female BALB/c mice were immunized with recombinant LIF protein emulsified in Freund's adjuvant to induce anti‐LIF antibodies. Tumors were subsequently established by subcutaneous injection of 4T1 breast cancer cells after antibody titers were confirmed. Serum cytokine levels (IFN‐γ, TNF‐α, IL‐6, IL‐10, IL‐4, and TGF‐β) were measured by ELISA, and tumor growth was monitored. Active immunization against LIF significantly inhibited tumor growth compared to controls. Serum analysis revealed that anti‐LIF immunization systemically suppressed tumor‐induced IL‐10 while significantly enhancing IFN‐γ levels in tumor‐bearing mice. In contrast, IL‐4 reduction was only significant in the absence of tumor challenge, and TNF‐α levels were generally reduced by the presence of the tumor regardless of immunization. Our findings suggest that vaccination against LIF can induce endogenous anti‐LIF antibody responses, limit tumor progression, and selectively modulate systemic cytokine profiles, particularly through suppression of tumor‐induced IL‐10 together with enhanced IFN‐γ responses in tumor‐bearing mice. These findings support further investigation of LIF‐targeted immunization as a potential immunotherapeutic strategy in breast cancer.